CD20+ Test

Your immune system runs on specialized cells, and B cells are one of its most important workers. They make antibodies, present targets to other immune cells, and shape how your body remembers infections. Counting CD20-positive cells gives you a window into how many of these B cells are circulating, whether they are being depleted by treatment, and whether something unusual is happening in your immune system.

CD20 (cluster of differentiation 20) is the surface marker used to identify mature B cells in the blood. It is also the target of some of the most widely used immune-modifying drugs in medicine, including rituximab and ocrelizumab. Whether you are tracking a known condition, monitoring a treatment, or simply curious about a layer of your immune system that a standard blood panel never measures, this number tells a story your routine labs cannot.

What CD20 Actually Is

CD20 is a small protein that sits on the surface of B cells and acts like a calcium channel, helping the cell respond to signals that drive its activation, growth, and maturation. It is encoded by the MS4A1 gene and shows up on B cells from the late pre-B stage through to mature B cells. It is absent from stem cells and from antibody-producing plasma cells, which is why anti-CD20 drugs can wipe out circulating B cells while leaving most of your existing antibody supply intact.

A small subset of T cells (a different type of immune cell) also expresses CD20 at low levels. These CD20-positive T cells appear in blood, lymph tissue, and cerebrospinal fluid and tend to be pro-inflammatory, producing high levels of signaling molecules. They are an emerging area of research, particularly in multiple sclerosis.

B-Cell Cancers and Leukemia

CD20 is one of the core markers used by pathologists to identify and classify B-cell cancers. Most B-cell lymphomas express CD20, and it is a defining marker for chronic lymphocytic leukemia (CLL) alongside CD19, CD5, CD23, and surface immunoglobulin light chains. The level and pattern of CD20 expression carry prognostic weight in several settings.

In adult B-cell precursor acute lymphoblastic leukemia (B-ALL), CD20 positivity (seen in roughly 40 to 50% of cases) has been linked to worse survival. In pediatric B-ALL, higher CD20 expression at diagnosis and rising expression on residual blasts at day 15 has been associated with inferior relapse-free survival in several series, though the picture is mixed across studies. In CLL, both surface CD20 density and a soluble form of CD20 found in plasma have been studied as prognostic markers, with higher circulating CD20 linked to advanced disease and shorter survival.

What this means for you: if you are being evaluated for a suspected B-cell cancer, CD20 will almost certainly be measured as part of a flow cytometry panel. It is not a one-marker diagnosis. It works alongside CD19, CD5, CD23, and other markers to identify the specific cell type involved.

Multiple Sclerosis and Autoimmune Disease

B cells play a central role in multiple sclerosis (MS), and depleting CD20-positive cells with drugs like ocrelizumab, ofatumumab, and rituximab sharply reduces relapses and new brain lesions on MRI. Pro-inflammatory CD20-positive T cells found in blood, cerebrospinal fluid, and central nervous system lesions appear to contribute to disease activity, and pretreatment levels of these cells have been linked to early disease activity after starting ocrelizumab.

Tracking CD20-positive cells is one way clinicians monitor whether B-cell-depleting therapy is working. After dosing, B cells fall sharply and stay low for months. When they return, they typically come back less mature and more activated than before, which may explain part of the long-lasting clinical effect.

Solid Tumors and the Immune Microenvironment

CD20 also marks B cells that have infiltrated solid tumors, and the meaning of a high count depends on the cancer type. In oral squamous cell carcinoma and thymic carcinoma, a high density of CD20-positive tumor-infiltrating B cells is associated with better survival. In renal cell carcinoma, the opposite pattern emerges: a minority of patients with high CD20-positive B-cell infiltration tend to have worse outcomes. A meta-analysis of melanoma found that high CD20-positive tumor-infiltrating lymphocytes correlated with favorable survival, with a hazard ratio around 0.49 (meaning roughly half the risk of death compared to those with low infiltration).

Why Higher Is Not Always Better, and Lower Is Not Always Worse

CD20 is not a simple "good number, bad number" marker. The same CD20-positive cell can mean very different things in different settings. A high count of CD20-positive lymphocytes in your blood is normal if you are healthy. A high CD20 expression on leukemia cells can signal worse prognosis. A high density of CD20-positive B cells in a solid tumor can be protective in some cancers and harmful in others. The number itself is meaningless without the clinical context. This is why CD20 is best interpreted alongside other immune markers and your overall picture, not in isolation.

Reference Ranges

There is no universally standardized "normal range" for circulating CD20-positive cells. The range below comes from a single study of 50 healthy adults in Oman measured by flow cytometry. It is illustrative orientation, not a target. Your lab will likely report different numbers, and ranges from other populations have not been published in this dataset.

Source: Al-Mawali et al., 2013, Omani healthy adults. Compare your results within the same lab over time for the most meaningful trend. A single number outside one cohort's range does not necessarily mean anything is wrong.

Disease-Specific Cutpoints

Cutpoints for CD20 used in cancer research are not population norms. They are tools for predicting outcomes in people who already have a diagnosis. In CLL, soluble CD20 above 2.2 ng/dL predicted higher cell fragility (smudge cells) with 69% sensitivity and 86% specificity. In de novo CLL, surface CD20 above 60.3% on leukemic cells correlated with longer treatment-free survival (90% sensitivity, 38% specificity). In pediatric B-ALL, CD20 mean fluorescence intensity above 8.08 at diagnosis or above 28.65 at day 15 correlated with worse overall survival. These are research thresholds, not screening tools.

Tracking Your Trend

A single CD20 reading is a snapshot. The real value comes from watching the number change over time, especially if you are starting or on an anti-CD20 therapy, monitoring a hematologic condition, or tracking your immune system as part of broader health surveillance. After a dose of rituximab or ocrelizumab, CD20-positive B cells fall to near zero and stay suppressed for months. Watching them return tells you something about how your immune system is recovering.

If you are healthy and curious, a reasonable approach is to get a baseline, retest in 3 to 6 months if you are making meaningful changes (starting an immunomodulating medication, recovering from a serious illness), and then track at least annually. If you are on B-cell-depleting therapy, your prescribing clinician will recommend a monitoring schedule built around dosing. Comparing values from the same lab matters because flow cytometry gating and antibody panels vary between labs.

When Results Can Be Misleading

• Recent or current anti-CD20 therapy: rituximab, ocrelizumab, ofatumumab, ublituximab, obinutuzumab, and similar drugs profoundly deplete CD20-positive cells for months. Any reading taken during or shortly after treatment reflects the drug, not your underlying immune system.
• Other immune-modifying drugs: medications like natalizumab can raise circulating B-cell numbers, while fingolimod can lower them. These shifts reflect drug effects, not new disease.
• Acute illness or infection: lymphocyte subsets shift during infections and can take weeks to normalize. A test done right after a viral illness may not reflect your usual baseline.
• Lab-to-lab variation: flow cytometry techniques, antibody clones, and gating strategies differ between labs, which means absolute numbers may not be directly comparable across providers.

What an Abnormal Result Should Trigger

If your CD20-positive cell count is unexpectedly low and you are not on B-cell-depleting therapy, the next step is to look at the rest of your immune cell panel: total lymphocytes, CD19, CD3, CD4, CD8, NK cells, and immunoglobulin levels. Persistently low B cells with low immunoglobulins can suggest a primary or secondary immunodeficiency worth investigating with an immunologist. If your count is unexpectedly high, especially with abnormal lymphocyte morphology on a complete blood count, the next step is a flow cytometry panel and review by a hematologist. CD20 should never be interpreted alone. Pair it with CD19, CD5, CD23, kappa and lambda light chains for B-cell workup, and with CD3, CD4, CD8 for the broader immune picture.